A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback